Stockhead on MSN
ASX Quarterly Health Wrap: Lumos lands US$317m deal as ReNerve and Vitrafy hit key milestones
The latest quarterly reporting season is underway, with investors tuning in to see how ASX-listed companies performed during ...
Alaska has been inundated with the scourge of drug overdoses, with the state ranking among the highest in the country for overdoses. There are no official reports for 2024 yet, ...
You can't expect your lender’s initial mortgage renewal offer to be a bargain. That’s why comparing the best mortgage renewal rates is an essential part of the renewal process. Many or all of the ...
The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1 billion investment programme. According to the Financial Times, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results